BIOGEN INC (1BIIB.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:1BIIB - US09062X1037 - Common Stock
157.4 EUR
+18.05 (+12.95%)
Taking everything into account, 1BIIB scores 6 out of 10 in our fundamental rating. 1BIIB was compared to 82 industry peers in the Biotechnology industry. 1BIIB gets an excellent profitability rating and is at the same time showing great financial health properties. 1BIIB has a bad growth rate and is valued cheaply. With these ratings, 1BIIB could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
1BIIB had positive earnings in the past year.
In the past year 1BIIB had a positive cash flow from operations.
Each year in the past 5 years 1BIIB has been profitable.
Each year in the past 5 years 1BIIB had a positive operating cash flow.
1.2 Ratios
1BIIB has a Return On Assets of 5.51%. This is amongst the best in the industry. 1BIIB outperforms 82.05% of its industry peers.
1BIIB has a Return On Equity of 8.84%. This is amongst the best in the industry. 1BIIB outperforms 83.33% of its industry peers.
1BIIB has a better Return On Invested Capital (9.70%) than 88.46% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1BIIB is in line with the industry average of 12.14%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
1BIIB has a better Profit Margin (15.98%) than 84.62% of its industry peers.
In the last couple of years the Profit Margin of 1BIIB has declined.
The Operating Margin of 1BIIB (28.50%) is better than 88.46% of its industry peers.
In the last couple of years the Operating Margin of 1BIIB has declined.
With a decent Gross Margin value of 75.24%, 1BIIB is doing good in the industry, outperforming 67.95% of the companies in the same industry.
In the last couple of years the Gross Margin of 1BIIB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
1BIIB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, 1BIIB has more shares outstanding
1BIIB has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, 1BIIB has an improved debt to assets ratio.
2.2 Solvency
1BIIB has an Altman-Z score of 3.21. This indicates that 1BIIB is financially healthy and has little risk of bankruptcy at the moment.
1BIIB's Altman-Z score of 3.21 is fine compared to the rest of the industry. 1BIIB outperforms 78.21% of its industry peers.
1BIIB has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as 1BIIB would need 2.78 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.78, 1BIIB belongs to the top of the industry, outperforming 82.05% of the companies in the same industry.
1BIIB has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
1BIIB's Debt to Equity ratio of 0.35 is in line compared to the rest of the industry. 1BIIB outperforms 52.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.21 |
ROIC/WACC1.18
WACC8.21%
2.3 Liquidity
1BIIB has a Current Ratio of 2.72. This indicates that 1BIIB is financially healthy and has no problem in meeting its short term obligations.
1BIIB has a Current ratio of 2.72. This is comparable to the rest of the industry: 1BIIB outperforms 58.97% of its industry peers.
1BIIB has a Quick Ratio of 2.04. This indicates that 1BIIB is financially healthy and has no problem in meeting its short term obligations.
1BIIB has a Quick ratio (2.04) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.51% over the past year.
The earnings per share for 1BIIB have been decreasing by -13.31% on average. This is quite bad
1BIIB shows a small growth in Revenue. In the last year, the Revenue has grown by 4.77%.
The Revenue has been decreasing by -7.62% on average over the past years.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
Based on estimates for the next years, 1BIIB will show a small growth in Earnings Per Share. The EPS will grow by 0.52% on average per year.
1BIIB is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.65% yearly.
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
1BIIB is valuated reasonably with a Price/Earnings ratio of 10.83.
Compared to the rest of the industry, the Price/Earnings ratio of 1BIIB indicates a rather cheap valuation: 1BIIB is cheaper than 93.59% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.39. 1BIIB is valued rather cheaply when compared to this.
1BIIB is valuated reasonably with a Price/Forward Earnings ratio of 11.61.
Based on the Price/Forward Earnings ratio, 1BIIB is valued cheaper than 97.44% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.84, 1BIIB is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.83 | ||
| Fwd PE | 11.61 |
4.2 Price Multiples
91.03% of the companies in the same industry are more expensive than 1BIIB, based on the Enterprise Value to EBITDA ratio.
92.31% of the companies in the same industry are more expensive than 1BIIB, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.75 | ||
| EV/EBITDA | 7.27 |
4.3 Compensation for Growth
1BIIB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
5. Dividend
5.1 Amount
No dividends for 1BIIB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1BIIB (11/27/2025, 7:00:00 PM)
157.4
+18.05 (+12.95%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap23.08B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.81
Price Target154.08 (-2.11%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)5.12%
PT rev (3m)3.09%
EPS NQ rev (1m)-54.11%
EPS NQ rev (3m)-55.25%
EPS NY rev (1m)-3.62%
EPS NY rev (3m)1.63%
Revenue NQ rev (1m)-2.3%
Revenue NQ rev (3m)-2.13%
Revenue NY rev (1m)0.92%
Revenue NY rev (3m)5.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.83 | ||
| Fwd PE | 11.61 | ||
| P/S | 2.64 | ||
| P/FCF | 11.75 | ||
| P/OCF | 10.83 | ||
| P/B | 1.46 | ||
| P/tB | 11.15 | ||
| EV/EBITDA | 7.27 |
EPS(TTM)14.53
EY9.23%
EPS(NY)13.55
Fwd EY8.61%
FCF(TTM)13.4
FCFY8.51%
OCF(TTM)14.53
OCFY9.23%
SpS59.6
BVpS107.8
TBVpS14.12
PEG (NY)N/A
PEG (5Y)N/A
Graham Number187.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.21 |
F-Score5
WACC8.21%
ROIC/WACC1.18
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year7.73%
EBIT Next 3Y2.84%
EBIT Next 5Y1.64%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / 1BIIB.MI FAQ
What is the ChartMill fundamental rating of BIOGEN INC (1BIIB.MI) stock?
ChartMill assigns a fundamental rating of 6 / 10 to 1BIIB.MI.
What is the valuation status for 1BIIB stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (1BIIB.MI). This can be considered as Undervalued.
Can you provide the profitability details for BIOGEN INC?
BIOGEN INC (1BIIB.MI) has a profitability rating of 7 / 10.
What is the earnings growth outlook for BIOGEN INC?
The Earnings per Share (EPS) of BIOGEN INC (1BIIB.MI) is expected to decline by -5.79% in the next year.